New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
May 24, 2022 11:29 ET
|
Biofrontera Inc.
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
May 24, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45 ET
|
BioNTech SE
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use AuthorizationThe third 3-µg dose was well-tolerated among 1,678...
Pfizer-BioNTech COVID-19-Impfstoff zeigt bei Kindern im Alter von 6 Monaten bis unter 5 Jahren nach drei Dosen starke Immunantworten, hohe Wirksamkeit und vorteilhaftes Sicherheitsprofil
May 23, 2022 06:45 ET
|
BioNTech SE
Basierend auf den ersten Studiendaten erfüllen drei Dosen des Pfizer-BioNTech COVID-19-Impfstoffs alle für die US-Notfallzulassung notwendigen Immunobridging-Kriterien (Vergleich der...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 20, 2022 13:53 ET
|
The Rosen Law Firm PA
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Axsome...
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
May 09, 2022 08:30 ET
|
CVRx, Inc.
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s...
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the First Quarter 2022
May 05, 2022 06:00 ET
|
22nd Century Group, Inc
Launched VLN® Pilot Program in Chicago with Circle K as First Retail Trade PartnerBegan VLN® Shipments to South Korea for First International LaunchFDA’s Proposed Menthol Ban Could Leave VLN® Menthol...
ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
May 04, 2022 16:53 ET
|
The Rosen Law Firm PA
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...